Mid Atlantic Bio Angels Invests in Salarius Pharmaceuticals
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Mid Atlantic Bio Angels (MABA) announces today that it has made an investment in Houston-based Salarius Pharmaceuticals, which is developing epigenetic treatments for cancer. Both the Mid Atlantic Bio Angels Pool II and individuals from the organization participated in the investment.
“Epigenetics has not been adequately explored as a potential solution for cancers, and Salarius is making headway in Phase 1 trials in several cancer types,” said Yaniv Sneor, a MABA co-founder and president of Blue Cactus Consulting, “We have confidence in the company’s experienced management team and look forward to seeing where the technology leads.”
Salarius is an oncology-based biotechnology company developing targeted treatments for patients who need them the most. Its lead compound, Seclidemstat, represents a potential paradigm shift in the treatment of cancer and is initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available. Moreover, Salarius believes that its technology may also enable it to develop treatments for other cancers such as prostate, breast, ovarian, and other conditions like leukemia.
Salarius is the recipient of a 3-year, $18.7 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award, is housed in the Johnson & Johnson JLABS@TMC facility in Houston, Texas and receives support from organizations like the National Pediatric Cancer Foundation. “An investment by Mid-Atlantic Bio Angels represents additional validation of Salarius’s science and strategy, but most importantly allows us to continue to pursue the development of cancer treatments for patients that need them the most,” said David Arthur, CEO of Salarius Pharmaceuticals.
About Mid Atlantic Bio AngelsMid Atlantic Bio Angels ( http://bioangels.net ) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA’s goal is to create an environment where the depth of investors’ knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.
CONTACT: Jules Abraham JQA Partners, Inc.email@example.com